Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: A report of the association for molecular pathology

Journal of Molecular Diagnostics

Volumn 15, Issue 6, 2013, Pages 733-744

  Gong, Jerald Z ^a,b   Cook, James R ^a,c   Greiner, Timothy C ^a,d   Hedvat, Cyrus ^a,e   Hill, Charles E ^a,f   Lim, Megan S ^a,g   Longtine, Janina A ^a,h   Sabath, Daniel ^a,i   Wang, Y Lynn ^a,j  

^a Association for Molecular Pathology   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ARTICLE; GENE; GENE MAPPING; GENE MUTATION; JANUS KINASE 2 GENE; MOLECULAR PATHOLOGY; MPL GENE; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE NEOPLASM; PRACTICE GUIDELINE;

DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; GENETIC TESTING; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; MYELOPROLIFERATIVE DISORDERS; RECEPTORS, THROMBOPOIETIN; REFERENCE STANDARDS;

EID: 84886043047     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2013.07.002     Document Type: Article

References (95)

1. R.L. Levine, M. Wadleigh, J. Cools, B.L. Ebert, G. Wernig, B.J. Huntly, T.J. Boggon, I. Wlodarska, J.J. Clark, S. Moore, J. Adelsperger, S. Koo, J.C. Lee, S. Gabriel, T. Mercher, A. D'Andrea, S. Frohling, K. Dohner, P. Marynen, P. Vandenberghe, R.A. Mesa, A. Tefferi, J.D. Griffin, M.J. Eck, W.R. Sellers, M. Meyerson, T.R. Golub, S.J. Lee, and D.G. Gilliland Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 2005 387 397
2. R. Kralovics, F. Passamonti, A.S. Buser, S.S. Teo, R. Tiedt, J.R. Passweg, A. Tichelli, M. Cazzola, and R.C. Skoda A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 2005 1779 1790
3. C. James, V. Ugo, J.P. Le Couédic, J. Staerk, F. Delhommeau, C. Lacout, L. Garçon, H. Raslova, R. Berger, A. Bennaceur-Griscelli, J.L. Villeval, S.N. Constantinescu, N. Casadevall, and W. Vainchenker A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 2005 1144 1148
4. E.J. Baxter, L.M. Scott, P.J. Campbell, C. East, N. Fourouclas, S. Swanton, G.S. Vassiliou, A.J. Bench, E.M. Boyd, N. Curtin, M.A. Scott, W.N. Erber, and A.R. Green Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [Erratum appeared in Lancet 2005, 366:122] Lancet 365 2005 1054 1061
5. L.M. Scott, W. Tong, R.L. Levine, M.A. Scott, P.A. Beer, M.R. Stratton, P.A. Futreal, W.N. Erber, M.F. McMullin, C.N. Harrison, A.J. Warren, D.G. Gilliland, H.F. Lodish, and A.R. Green JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis N Engl J Med 356 2007 459 468
6. Y. Pikman, B.H. Lee, T. Mercher, E. McDowell, B.L. Ebert, M. Gozo, A. Cuker, G. Wernig, S. Moore, I. Galinsky, D.J. DeAngelo, J.J. Clark, S.J. Lee, T.R. Golub, M. Wadleigh, D.G. Gilliland, and R.L. Levine MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia PLoS Med 3 2006 e270
7. A.D. Pardanani, R.L. Levine, T. Lasho, Y. Pikman, R.A. Mesa, M. Wadleigh, D.P. Steensma, M.A. Elliott, A.P. Wolanskyj, W.J. Hogan, R.F. McClure, M.R. Litzow, D.G. Gilliland, and A. Tefferi MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Blood 108 2006 3472 3476
8. P.A. Beer, P.J. Campbell, L.M. Scott, A.J. Bench, W.N. Erber, D. Bareford, B.S. Wilkins, J.T. Reilly, H.C. Hasselbalch, R. Bowman, K. Wheatley, G. Buck, C.N. Harrison, and A.R. Green MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort Blood 112 2008 141 149
9. J. Thiele, H.M. Kvasnika, A. Orazi, A. Tefferi, and G. Birgegard Polycythaemia vera. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman, ed 4. 2008 IARC Press Lyon 40 43
10. J. Thiele, H.M. Kvasnicka, A. Orazi, A. Tefferi, and H. Gisslinger Essential thrombocythaemia. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman, ed 4. 2008 IARC Press Lyon 48 50
11. J. Thiele, H.M. Kvasnicka, A. Tefferi, G. Barosi, A. Orazi, and J.W. Vardiman Primary myelofibrosis. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman, ed 4. 2008 IARC Press Lyon 44 47
12. N. Carbuccia, A. Murati, V. Trouplin, M. Brecqueville, J. Adélaide, J. Rey, W. Vainchenker, O.A. Bernard, M. Chaffanet, N. Vey, D. Birnbaum, and M.J. Mozziconacci Mutations of ASXL1 gene in myeloproliferative neoplasms Leukemia 23 2009 2183 2186
13. T. Ernst, A.J. Chase, J. Score, C.E. Hidalgo-Curtis, C. Bryant, A.V. Jones, K. Waghorn, K. Zoi, F.M. Ross, A. Reiter, A. Hochhaus, H.G. Drexler, A. Duncombe, F. Cervantes, D. Oscier, J. Boultwood, F.H. Grand, and N.C. Cross Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Nat Genet 42 2010 722 726
14. A. Tefferi, T.L. Lasho, O. Abdel-Wahab, P. Guglielmelli, J. Patel, D. Caramazza, L. Pieri, C.M. Finke, O. Kilpivaara, M. Wadleigh, M. Mai, R.F. McClure, D.G. Gilliland, R.L. Levine, A. Pardanani, and A.M. Vannucchi IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis Leukemia 24 2010 1302 1309
15. F. Stegelmann, L. Bullinger, R.F. Schlenk, P. Paschka, M. Griesshammer, C. Blersch, S. Kuhn, S. Schauer, H. Dohner, and K. Dohner DNMT3A mutations in myeloproliferative neoplasms Leukemia 25 2011 1217 1219
16. F.H. Grand, C.E. Hidalgo-Curtis, T. Ernst, K. Zoi, C. Zoi, C. McGuire, S. Kreil, A. Jones, J. Score, G. Metzgeroth, D. Oscier, A. Hall, C. Brandts, H. Serve, A. Reiter, A.J. Chase, and N.C. Cross Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms Blood 113 2009 6182 6192
17. A.M. Vannucchi, T.L. Lasho, P. Guglielmelli, F. Biamonte, A. Pardanani, A. Pereira, C. Finke, J. Score, N. Gangat, C. Mannarelli, R.P. Ketterling, G. Rotunno, R.A. Knudson, M.C. Susini, R.R. Laborde, A. Spolverini, A. Pancrazzi, L. Pieri, R. Manfredini, E. Tagliafico, R. Zini, A. Jones, K. Zoi, A. Reiter, A. Duncombe, D. Pietra, E. Rumi, F. Cervantes, G. Barosi, M. Cazzola, N.C. Cross, and A. Tefferi Mutations and prognosis in primary myelofibrosis Leukemia 27 2013 1861 1869
18. D.P. Steensma, G.W. Dewald, T.L. Lasho, H.L. Powell, R.F. McClure, R.L. Levine, D.G. Gilliland, and A. Tefferi The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes Blood 106 2005 1207 1209
19. J.W. Lee, Y.G. Kim, Y.H. Soung, K.J. Han, S.Y. Kim, H.S. Rhim, W.S. Min, S.W. Nam, W.S. Park, J.Y. Lee, N.J. Yoo, and S.H. Lee The JAK2 V617F mutation in de novo acute myelogenous leukemias Oncogene 25 2006 1434 1436
20. C.G. Mullighan, J. Zhang, R.C. Harvey, J.R. Collins-Underwood, B.A. Schulman, L.A. Phillips, S.K. Tasian, M.L. Loh, X. Su, W. Liu, M. Devidas, S.R. Atlas, I.M. Chen, R.J. Clifford, D.S. Gerhard, W.L. Carroll, G.H. Reaman, M. Smith, J.R. Downing, S.P. Hunger, and C.L. Willman JAK mutations in high-risk childhood acute lymphoblastic leukemia Proc Natl Acad Sci USA 106 2009 9414 9418
21. L.M. Scott, P.J. Campbell, E.J. Baxter, T. Todd, P. Stephens, S. Edkins, R. Wooster, M.R. Stratton, P.A. Futreal, and A.R. Green The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders Blood 106 2005 2920 2921
22. M. Cankovic, L. Whiteley, R.C. Hawley, R.J. Zarbo, and D. Chitale Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods Am J Clin Pathol 132 2009 713 721
23. P. Saharinen, K. Takaluoma, and O. Silvennoinen Regulation of the Jak2 tyrosine kinase by its pseudokinase domain Mol Cell Biol 20 2000 3387 3395
24. K. Yamaoka, P. Saharinen, M. Pesu, V.E. Holt 3rd, O. Silvennoinen, and J.J. O'Shea The Janus kinases (Jaks) Genome Biol 5 2004 253
25. I. Warshawsky, F. Mularo, C. Hren, and M. Jakubowski Failure of the Ipsogen MutaScreen kit to detect the JAK2 617V>F mutation in samples with additional rare exon 14 mutations: implications for clinical testing and report of a novel 618C>F mutation in addition to 617V>F Blood 115 2010 3175 3176
26. F. Grünebach, U. Bross-Bach, L. Kanz, and P. Brossart Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera Leukemia 20 2006 2210 2211
27. C. Cleyrat, J. Jelinek, F. Girodon, M. Boissinot, T. Ponge, J.L. Harousseau, J.P. Issa, and S. Hermouet JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5 Leukemia 24 2010 1069 1073
28. C.L. Wong, E.S. Ma, C.L. Wang, H.Y. Lam, and S.Y. Ma JAK2 V617F due to a novel TG -> CT mutation at nucleotides 1848-1849: diagnostic implication Leukemia 21 2007 1344 1346
29. S. Schnittger, U. Bacher, W. Kern, M. Schröder, T. Haferlach, and C. Schoch Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E Leukemia 20 2006 2195 2197
30. D. Pietra, S. Li, A. Brisci, F. Passamonti, E. Rumi, A. Theocharides, M. Ferrari, H. Gisslinger, R. Kralovics, L. Cremonesi, R. Skoda, and M. Cazzola Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders Blood 111 2008 1686 1689
31. S. Schnittger, U. Bacher, C. Haferlach, T. Geer, P. Müller, J. Mittermüller, P. Petrides, R. Schlag, R. Sandner, J. Selbach, H.R. Slawik, H.W. Tessen, J. Wehmeyer, W. Kern, and T. Haferlach Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera Haematologica 94 2009 414 418
32. S. Carillo, L. Henry, E. Lippert, F. Girodon, I. Guiraud, C. Richard, F. Dubois Galopin, C. Cleyrat, E. Jourdan, R. Kralovics, S. Hermouet, and T. Lavabre-Bertrand Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations-clinical relevance in the monitoring of polycythemia J Mol Diagn 13 2011 263 270
33. A. Siemiatkowska, M. Bieniaszewska, A. Hellmann, and J. Limon JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms Leuk Res 34 2010 387 389
34. T. Burjanivova, J. Marcinek, Z. Lasabova, G. Minarik, P. Szepe, T. Balharek, A. Vanochova, H. Polacek, and L. Plank A novel JAK2 exon 12 mutation identified in the retrospective analysis of paraffin-embedded tissues of polycythemia vera patients Diagn Mol Pathol 18 2009 108 111
35. H. Cario, K. Schwarz, J.M. Herter, V. Komrska, M.F. McMullin, M. Minkov, C. Niemeyer, D. Pospisilova, H. Reinhard, K.M. Debatin, and H.L. Pahl Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera Br J Haematol 142 2008 622 626
36. D.M. Williams, A.H. Kim, O. Rogers, J.L. Spivak, and A.R. Moliterno Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis Exp Hematol 35 2007 1641 1646
37. L. Martínez-Avilés, C. Besses, A. Alvarez-Larrán, F. Cervantes, J.C. Hernández-Boluda, and B. Bellosillo JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis Haematologica 92 2007 1717 1718
38. M. Bernardi, M. Ruggeri, E. Albiero, D. Madeo, and F. Rodeghiero Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation Am J Hematol 84 2009 258 260
39. C.M. Butcher, U. Hahn, L.B. To, J. Gecz, E.J. Wilkins, H.S. Scott, P.G. Bardy, and R.J. D'Andrea Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients Leukemia 22 2008 870 873
40. S. Li, R. Kralovics, G. De Libero, A. Theocharides, H. Gisslinger, and R.C. Skoda Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations Blood 111 2008 3863 3866
41. Y.M. Yeh, Y.L. Chen, H.Y. Cheng, W.C. Su, N.H. Chow, T.Y. Chen, and C.L. Ho High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera Am J Clin Pathol 134 2010 266 270
42. D. Colaizzo, L. Amitrano, G.L. Tiscia, E. Grandone, M.A. Guardascione, and M. Margaglione A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis Blood 110 2007 2768 2769
43. M.J. Percy, L.M. Scott, W.N. Erber, C.N. Harrison, J.T. Reilly, F.G. Jones, A.R. Green, and M.F. McMullin The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels Haematologica 92 2007 1607 1614
44. J.H. Ohyashiki, H. Hisatomi, S. Shimizu, M. Sugaya, and K. Ohyashiki Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis Jpn J Clin Oncol 39 2009 509 513
45. A. Pardanani, T.L. Lasho, C. Finke, C.A. Hanson, and A. Tefferi Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera Leukemia 21 2007 1960 1963
46. E. Albiero, D. Madeo, M. Ruggeri, M. Bernardi, A. Giorgetti, and F. Rodeghiero Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis Br J Haematol 142 2008 986 990
47. W. Ma, H. Kantarjian, X. Zhang, C.H. Yeh, Z.J. Zhang, S. Verstovsek, and M. Albitar Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias J Mol Diagn 11 2009 49 53
48. L.M. Scott The JAK2 exon 12 mutations: a comprehensive review Am J Hematol 86 2011 668 676
49. B. Röthlisberger, A. Huber, M. Bargetzi, A. Mendez, and M. Heizmann JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera Leuk Lymphoma 49 2008 586 588
50. A. Karow, C. Waller, C. Reimann, C.M. Niemeyer, and C.P. Kratz JAK2 mutations other than V617F: a novel mutation and mini review Leuk Res 32 2008 365 366
51. J.G. Drachman, and K. Kaushansky Structure and function of the cytokine receptor superfamily Curr Opin Hematol 2 1995 22 28
52. J. Staerk, C. Lacout, T. Sato, S.O. Smith, W. Vainchenker, and S.N. Constantinescu An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor Blood 107 2006 1864 1871
53. M.P. Lambert, J. Jiang, V. Batra, C. Wu, and W. Tong A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia Am J Hematol 87 2012 532 534
54. D. Pietra, A. Brisci, E. Rumi, S. Boggi, C. Elena, A. Pietrelli, R. Bordoni, M. Ferrari, F. Passamonti, G. De Bellis, L. Cremonesi, and M. Cazzola Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms Haematologica 96 2011 607 611
55. J. Ding, H. Komatsu, A. Wakita, M. Kato-Uranishi, M. Ito, A. Satoh, K. Tsuboi, M. Nitta, H. Miyazaki, S. Iida, and R. Ueda Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin Blood 103 2004 4198 4200
56. R. Chaligné, C. Tonetti, R. Besancenot, L. Roy, C. Marty, P. Mossuz, J.J. Kiladjian, G. Socié, D. Bordessoule, M.C. Le Bousse-Kerdilès, W. Vainchenker, and S. Giraudier New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition Leukemia 22 2008 1557 1566
57. T.C. Greiner Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders Am J Clin Pathol 125 2006 651 653
58. A. Tefferi, P. Noel, and C.A. Hanson Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology J Mol Diagn 13 2011 461 466
59. M. Boissinot, E. Lippert, F. Girodon, I. Dobo, M. Fouassier, C. Masliah, V. Praloran, and S. Hermouet Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis Blood 108 2006 3223 3224
60. M. Boissinot, R. Garand, M. Hamidou, and S. Hermouet The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS) Blood 108 2006 1781 1782
61. T.S. Larsen, N. Pallisgaard, M.B. Møller, and H.C. Hasselbalch Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow Leukemia 22 2008 194 195
62. J.J. Kiladjian, B. Cassinat, P. Turlure, N. Cambier, M. Roussel, S. Bellucci, M.L. Menot, G. Massonnet, J.L. Dutel, K. Ghomari, P. Rousselot, M.J. Grange, Y. Chait, W. Vainchenker, N. Parquet, L. Abdelkader-Aljassem, J.F. Bernard, J.D. Rain, S. Chevret, C. Chomienne, and P. Fenaux High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a Blood 108 2006 2037 2040
63. A. Pardanani, J.R. Gotlib, C. Jamieson, J.E. Cortes, M. Talpaz, R.M. Stone, M.H. Silverman, D.G. Gilliland, J. Shorr, and A. Tefferi Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis J Clin Oncol 29 2011 789 796
64. S. Verstovsek, H. Kantarjian, R.A. Mesa, A.D. Pardanani, J. Cortes-Franco, D.A. Thomas, Z. Estrov, J.S. Fridman, E.C. Bradley, S. Erickson-Viitanen, K. Vaddi, R. Levy, and A. Tefferi Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N Engl J Med 363 2010 1117 1127
65. N. Kröger, A. Badbaran, E. Holler, J. Hahn, G. Kobbe, M. Bornhäuser, A. Reiter, T. Zabelina, A.R. Zander, and B. Fehse Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis Blood 109 2007 1316 1321
66. E. Hammond, K. Shaw, B. Carnley, S. P'ng, I. James, and R. Herrmann Quantitative determination of JAK2 V617F by TaqMan: an absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders J Mol Diagn 9 2007 242 248
67. J.D. Merker, C.D. Jones, S.T. Oh, I. Schrijver, J. Gotlib, and J.L. Zehnder Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory J Mol Diagn 12 2010 58 64
68. B. Denys, H. El Housni, F. Nollet, B. Verhasselt, and J. Philippé A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide J Mol Diagn 12 2010 512 519
69. T.S. Larsen, N. Pallisgaard, M.B. Møller, and H.C. Hasselbalch The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype Eur J Haematol 79 2007 508 515
70. R. McClure, M. Mai, and T. Lasho Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders Leukemia 20 2006 168 171
71. A.V. Jones, S. Kreil, K. Zoi, K. Waghorn, C. Curtis, L. Zhang, J. Score, R. Seear, A.J. Chase, F.H. Grand, H. White, C. Zoi, D. Loukopoulos, E. Terpos, E.C. Vervessou, B. Schultheis, M. Emig, T. Ernst, E. Lengfelder, R. Hehlmann, A. Hochhaus, D. Oscier, R.T. Silver, A. Reiter, and N.C. Cross Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders Blood 106 2005 2162 2168
72. G. Murugesan, S. Aboudola, H. Szpurka, M.A. Verbic, J.P. Maciejewski, R.R. Tubbs, and E.D. Hsi Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis Am J Clin Pathol 125 2006 625 633
73. J. Jelinek, Y. Oki, V. Gharibyan, C. Bueso-Ramos, J.T. Prchal, S. Verstovsek, M. Beran, E. Estey, H.M. Kantarjian, and J.P. Issa JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia Blood 106 2005 3370 3373
74. G.C. Shepard, H.L. Lawson, G.A. Hawkins, and J. Owen BsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2 Int J Lab Hematol 33 2011 267 271
75. M. Sattler, C. Walz, B.J. Crowley, E. Lengfelder, P.A. Jänne, A.M. Rogers, Y. Kuang, R.J. Distel, A. Reiter, and J.D. Griffin A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples Blood 107 2006 1237 1238
76. I. Rapado, S. Grande, E. Albizua, R. Ayala, J.A. Hernández, M. Gallardo, F. Gilsanz, and J. Martinez-Lopez High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms J Mol Diagn 11 2009 155 161
77. T.S. Laughlin, A.R. Moliterno, B.L. Stein, and P.G. Rothberg Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing [Erratum appeared in J Mol Diagn 2010, 12:730] J Mol Diagn 12 2010 278 282
78. W. Ma, H. Kantarjian, X. Zhang, X. Wang, Z. Zhang, C.H. Yeh, S. O'Brien, F. Giles, J.M. Bruey, and M. Albitar JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms PLoS One 5 2010 e12165
79. E. Vakil, and A. Tefferi BCR-ABL1-negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment Clin Lymphoma Myeloma Leuk 11 Suppl 1 2011 S37 S45
80. S. Hermouet, I. Dobo, E. Lippert, M.C. Boursier, L. Ergand, F. Perrault-Hu, and D. Pineau Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F) Leukemia 21 2007 1128 1130
81. Q. Chen, P. Lu, A.V. Jones, N.C. Cross, R.T. Silver, and Y.L. Wang Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders J Mol Diagn 9 2007 272 276
82. Y.L. Wang, J.W. Lee, J.S. Kui, A. Chadburn, N.C. Cross, D.M. Knowles, and M. Coleman Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals Acta Haematol 118 2007 209 214
83. E. Lippert, M. Boissinot, R. Kralovics, F. Girodon, I. Dobo, V. Praloran, N. Boiret-Dupré, R.C. Skoda, and S. Hermouet The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera Blood 108 2006 1865 1867
84. A.M. Vannucchi, E. Antonioli, P. Guglielmelli, G. Longo, A. Pancrazzi, V. Ponziani, C. Bogani, P.R. Ferrini, A. Rambaldi, V. Guerini, A. Bosi, and T. Barbui MPD Research Consortium: Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden Leukemia 21 2007 1952 1959
85. R.T. Silver, K. Vandris, Y.L. Wang, F. Adriano, A.V. Jones, P.J. Christos, and N.C. Cross JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy Leuk Res 35 2011 177 182
86. S. Malak, M. Labopin, C. Saint-Martin, C. Bellanne-Chantelot, and A. Najman French Group of Familial Myeloproliferative Disorders: Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications Blood Cells Mol Dis 49 2012 170 176
87. R.E. Gale, A.J. Allen, M.J. Nash, and D.C. Linch Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years Blood 109 2007 1241 1243
88. Y.L. Wang, K. Vandris, A. Jones, N.C. Cross, P. Christos, F. Adriano, and R.T. Silver JAK2 Mutations are present in all cases of polycythemia vera Leukemia 22 2008 1289
89. E. Antonioli, P. Guglielmelli, G. Poli, C. Bogani, A. Pancrazzi, G. Longo, V. Ponziani, L. Tozzi, L. Pieri, V. Santini, A. Bosi, A.M. Vannucchi Myeloproliferative Disorders Research Consortium (MPD-RC) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia Haematologica 93 2008 41 48
90. P. Sidon, H. El Housni, B. Dessars, and Heimann P The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors Leukemia 20 2006 1622
91. C. Martinaud, P. Brisou, and M.J. Mozziconacci Is the JAK2(V617F) mutation detectable in healthy volunteers? Am J Hematol 85 2010 287 288
92. G. Minnucci, G. Amicarelli, S. Salmoiraghi, O. Spinelli, M.L. Guinea Montalvo, U. Giussani, D. Adlerstein, and A. Rambaldi A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms Haematologica 97 2012 1394 1400
93. M.L. Gulley, R.M. Braziel, K.C. Halling, E.D. Hsi, J.A. Kant, M.N. Nikiforova, J.A. Nowak, S. Ogino, A. Oliveira, H.F. Polesky, L. Silverman, R.R. Tubbs, V.M. Van Deerlin, G.H. Vance, J. Versalovic Molecular Pathology Resource Committee, College of American Pathologists Clinical laboratory reports in molecular pathology Arch Pathol Lab Med 131 2007 852 863
94. C. Buors, N. Douet-Guilbert, F. Morel, L. Lecucq, B. Cassinat, and V. Ugo Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number Blood Cancer J 2 2012 e66
95. A. Kohlmann, H.U. Klein, S. Weissmann, S. Bresolin, T. Chaplin, H. Cuppens, E. Haschke-Becher, B. Garicochea, V. Grossmann, B. Hanczaruk, K. Hebestreit, C. Gabriel, I. Iacobucci, J.H. Jansen, G. te Kronnie, L. van de Locht, G. Martinelli, K. McGowan, M.R. Schweiger, B. Timmermann, P. Vandenberghe, B.D. Young, M. Dugas, and T. Haferlach The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories Leukemia 25 2011 1840 1848